DDDD.L Share News (DDDD)

DDDD.L Information

There is currently no data for DDDD

4d Pharma Says Blautix Treatment Meets Primary Endpoint In Trial

Mon, 23rd May 2016 06:58

LONDON (Alliance News) - Biotherapeutics developer 4d Pharma PLC on Monday said its irritable bowel syndrome treatment Blautix met its primary endpoint in its recently-completed phase 1 trial.

The trial showed Blautix to be safe and well-tolerated, meaning it met its primary endpoint, 4d Pharma said.

Data from the trials is being collected, and 4d said it will provide further information in this in coming weeks.

"This is a further step towards taking our pipeline, and live biotherapeutics as a class, to market approval. We have shown Blautix to be safe and well tolerated, which we have always believed would be a keystone to the field of live biotherapeutics," said 4d Chief Executive Duncan Peyton.

By Sam Unsted; samunsted@alliancenews.com; @SamUAtAlliance

More News

2 Feb 2015 16:06

UK AGM, EGM Calendar - Week Ahead

21 Jan 2015 08:51

4D Pharma Raises GBP34.8 Million Through Share Placing (ALLISS)

23 Sep 2014 12:24

4d Pharma Posts First-Half Loss, Says Pipeline Is Strong

2 Sep 2014 10:21

4D pharma progresses with IBS and Crohn's treatments

4D pharma has announced that its treatments for Irritable Bowel Syndrome (IBS) and Paediatric Crohn's Disease (PCD) are expected to enter clinical studies in the second quarter of 2015. The studies, which will be focused on evaluating safety and tolerability of the products as well as some clinica

2 Sep 2014 07:26

UK MORNING BRIEFING: Weir Group Leads Firm London Market On Upgrade

2 Sep 2014 06:55

4d Pharma's Blautix, Thetanix To Start Clinical Studies In 2015

7 Aug 2014 08:28

4d Pharma Gets Orphan Drug Designation From US FDA

7 Aug 2014 07:32

UK MORNING BRIEFING: Old Mutual, Coca-Cola HBC And RSA Weigh On FTSE

18 Jul 2014 10:00

4d Pharma Buys Microbiota For GBP2.0 Million

18 Jul 2014 07:25

UK MORNING BRIEFING: Shares Lower On Ukraine Crash, Gaza Offensive

25 Jun 2014 10:11

4d Pharma Raises GBP21.5 Million In Share Placing

25 Jun 2014 07:40

UK MORNING BRIEFING: Shares Down; Land Securities Buys Into Bluewater

4 Jun 2014 10:17

4d Pharma Raises Stake In GT Biologics To 83.5%

LONDON (Alliance News) - 4d Pharma PLC Wednesday said it has acquired a further 37.5% stake in GT Biologics Ltd for GBP1.22 million in new 4d Pharma shares, taking its total shareholding in the GT Biologics to 83.5%. 4d Pharma, which focuses on significant new therapeutic areas, said the ac

4 Jun 2014 07:53

4d pharma increases stake in GT Biologics to nearly 84%

4d pharma, an AIM-listed pharmaceutical company focused on new therapeutic areas, has added an additional 37.5% to its stake in GT Biologics taking its current holding to around 83.5%. The £1.22m consideration was satisfied by the issue of 699,500 new 4d shares at 175p each, reflecting their avera

Latest Share Chat

DDDD.L Share News (DDDD)

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

4d Pharma Says Blautix Treatment Meets Primary Endpoint In Trial

Login to your account

Quickpicks are a member only feature

Login to your account